New research estimates that protection from influenza vaccine in the United States was 33% to 42% in 2022-23 and also benefitted unvaccinated people, despite a second study noting a decline in vaccine coverage from 2022 to 2024, even among groups with a history of strong uptake.

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based combination shot that targets both influenza and COVID-19. Now, the entire vaccine sector is sizing up a new regulatory world,

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 percent higher in participants who were aged 65 years or older. Previous trial data showed that mRNA-1010 generated higher immune responses in participants than both regular standard flu shots and high-dose flu shots.

Annual influenza vaccines protect against four strains of flu, but because the strains circulating in people can change so much, we typically need an entirely new vaccine each year to help prevent ...

In the 2019-2020 year, the flu vaccine prevented an estimated 105,000 influenza-associated hospitalizations. The second reason to get the flu vaccine is to reduce infection.